Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ZDHHC20 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ZDHHC20 Recombinant Protein (Catalytic Domain) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for biochemical screening. |
View ZDHHC20 Products |
| Gene Delivery | ZDHHC20 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based palmitoylation assays. |
View ZDHHC20 Products |
| Benchmark Ab | Anti-ZDHHC20 Recombinant Antibody Sequence-verified positive control for Western Blot, IP, and immunofluorescence. |
View ZDHHC20 Products |
| Validator | ZDHHC20 siRNA Set For knockdown verification in target validation assays. |
View ZDHHC20 Products |
| Related Target A | EGFR ZDHHC20-mediated palmitoylation of EGFR regulates its dimerization, activation, and downstream signaling. Overcoming TKI resistance. |
View EGFR Products |
| Related Target B | CD274 (PD-L1) ZDHHC20 palmitoylates PD-L1, preventing its lysosomal degradation. Target synergy for immunotherapy. |
View CD274 Products |
| Related Target C | ZDHHC9 Homologous DHHC family member required for selectivity counter-screening panels. |
View ZDHHC9 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-pass transmembrane protein conformation loss | Lentivirus Premade Particles for stable cell line generation to preserve native 4-transmembrane structure. |
| Off-target screening against other DHHC family enzymes | Homolog panel proteins (e.g., ZDHHC9, ZDHHC17) strictly sequence-verified and quality-controlled. |
| Lack of reliable positive control antibodies | Recombinant Sequence-Verified Biosimilar Antibodies included |
| High background in cell-based palmitoylation assays | Highly validated siRNA knockdown sets to confirm assay specificity |
Live ZDHHC20 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ZDHHC20 therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum palmitoylation inhibitors to highly selective small molecule inhibitors and PROTACs. As first-generation covalent inhibitors reach preclinical and early clinical validation, the next wave of R&D is targeting the disruption of specific protein-protein interactions (such as the ZDHHC20-EGFR and ZDHHC20-PD-L1 interfaces) to overcome tyrosine kinase inhibitor (TKI) resistance and immune evasion in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors (Covalent) | Academic institutions, Emerging Biotechs | NSCLC (EGFR-mutant), Colorectal Cancer | Selectivity Assay (Need ZDHHC9/ZDHHC20 mutant vs WT recombinant proteins) |
| PROTACs / Degraders | Targeted Protein Degradation (TPD) companies | Breast Cancer, Solid Tumors | Degradation kinetics validation (Need Lentivirus for stable reporter cell lines) |
| Combination Therapies (with TKIs) | Oncology-focused Biopharma | TKI-resistant NSCLC | Synergy validation (Need EGFR mutant proteins and ZDHHC20 siRNA validation) |